福建海西新药创制股份有限公司（以下简称“公司”）于2026年1月7日提交了截至2025年12月31日的月度股份变动报告。报告显示，公司本月并未进行任何新增发行、购回及注销或库藏股活动，股本结构保持稳定。
公司报告期内的法定/注册股本维持人民币78,707,270元，普通股（H股）已发行股数与上月一致，分别为78,707,270股。面值为每股人民币1元。报告中并无提及任何期权、认股权证、可换股票据或其他协议安排的变动情况。
截至2025年12月31日，公司总股本为78,707,270股，无增减变化。公司表示遵守香港联合交易所有限公司证券上市规则及相关法律规定。
本次公告由公司联席公司秘书张俊环签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.